Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies

Vanderwalde Ari, C. L. Sun, L. Laddaran, L. Francisco, S. Armenian, J. Berano-Teh, F. L. Wong, L. Popplewell, G. Somlo, A. S. Stein, A. Nademanee, A. Krishnan, N. Kogut, S. J. Forman, S. Bhatia

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The probability of survival is conventionally calculated from autologous hematopoietic cell transplantation (aHCT). Conditional survival takes into account the changing probability of survival with time survived, but this is not known for aHCT populations. We determined disease- and cause-specific conditional survival for 2388 patients treated with aHCT over a period of 20 years at a single institution. A total of 1054 deaths (44% of the cohort) were observed: 78% attributed to recurrent disease; 9% to subsequent malignancies and 6% to cardiopulmonary disease. Estimated probability of relative survival was 62% at 5 years and 50% at 10 years from aHCT. On the other hand, the 5-year relative survival was 70, 75, 81 and 88% after having survived 1, 2, 5 and 10 years after aHCT, respectively. The cohort was at a 13.9-fold increased risk of death compared with the general population (95% confidence interval (CI)=13.1-14.8). The risk of death approached that of the general population for 10-year survivors (standardized mortality ratio (SMR)=1.4, 95% CI=0.9-1.9), with the exception of female Hodgkin's lymphoma patients transplanted before 1995 at age ≤40 years (SMR=6.0, 95% CI=1.9-14.0). Among those who had survived 10 years, nonrelapse-related mortality rates exceeded relapse-related mortality rates. This study provides clinically relevant survival estimates after aHCT, and helps inform interventional strategies.

Original languageEnglish (US)
Pages (from-to)1139-1145
Number of pages7
JournalLeukemia
Volume27
Issue number5
DOIs
StatePublished - May 1 2013
Externally publishedYes

Fingerprint

Cell Transplantation
Hematologic Neoplasms
Survival
Mortality
Confidence Intervals
Population
Hodgkin Disease
Survivors
Recurrence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies. / Ari, Vanderwalde; Sun, C. L.; Laddaran, L.; Francisco, L.; Armenian, S.; Berano-Teh, J.; Wong, F. L.; Popplewell, L.; Somlo, G.; Stein, A. S.; Nademanee, A.; Krishnan, A.; Kogut, N.; Forman, S. J.; Bhatia, S.

In: Leukemia, Vol. 27, No. 5, 01.05.2013, p. 1139-1145.

Research output: Contribution to journalArticle

Ari, V, Sun, CL, Laddaran, L, Francisco, L, Armenian, S, Berano-Teh, J, Wong, FL, Popplewell, L, Somlo, G, Stein, AS, Nademanee, A, Krishnan, A, Kogut, N, Forman, SJ & Bhatia, S 2013, 'Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies', Leukemia, vol. 27, no. 5, pp. 1139-1145. https://doi.org/10.1038/leu.2012.311
Ari, Vanderwalde ; Sun, C. L. ; Laddaran, L. ; Francisco, L. ; Armenian, S. ; Berano-Teh, J. ; Wong, F. L. ; Popplewell, L. ; Somlo, G. ; Stein, A. S. ; Nademanee, A. ; Krishnan, A. ; Kogut, N. ; Forman, S. J. ; Bhatia, S. / Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies. In: Leukemia. 2013 ; Vol. 27, No. 5. pp. 1139-1145.
@article{7ee06c55303446909074832b6e18c2ed,
title = "Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies",
abstract = "The probability of survival is conventionally calculated from autologous hematopoietic cell transplantation (aHCT). Conditional survival takes into account the changing probability of survival with time survived, but this is not known for aHCT populations. We determined disease- and cause-specific conditional survival for 2388 patients treated with aHCT over a period of 20 years at a single institution. A total of 1054 deaths (44{\%} of the cohort) were observed: 78{\%} attributed to recurrent disease; 9{\%} to subsequent malignancies and 6{\%} to cardiopulmonary disease. Estimated probability of relative survival was 62{\%} at 5 years and 50{\%} at 10 years from aHCT. On the other hand, the 5-year relative survival was 70, 75, 81 and 88{\%} after having survived 1, 2, 5 and 10 years after aHCT, respectively. The cohort was at a 13.9-fold increased risk of death compared with the general population (95{\%} confidence interval (CI)=13.1-14.8). The risk of death approached that of the general population for 10-year survivors (standardized mortality ratio (SMR)=1.4, 95{\%} CI=0.9-1.9), with the exception of female Hodgkin's lymphoma patients transplanted before 1995 at age ≤40 years (SMR=6.0, 95{\%} CI=1.9-14.0). Among those who had survived 10 years, nonrelapse-related mortality rates exceeded relapse-related mortality rates. This study provides clinically relevant survival estimates after aHCT, and helps inform interventional strategies.",
author = "Vanderwalde Ari and Sun, {C. L.} and L. Laddaran and L. Francisco and S. Armenian and J. Berano-Teh and Wong, {F. L.} and L. Popplewell and G. Somlo and Stein, {A. S.} and A. Nademanee and A. Krishnan and N. Kogut and Forman, {S. J.} and S. Bhatia",
year = "2013",
month = "5",
day = "1",
doi = "10.1038/leu.2012.311",
language = "English (US)",
volume = "27",
pages = "1139--1145",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies

AU - Ari, Vanderwalde

AU - Sun, C. L.

AU - Laddaran, L.

AU - Francisco, L.

AU - Armenian, S.

AU - Berano-Teh, J.

AU - Wong, F. L.

AU - Popplewell, L.

AU - Somlo, G.

AU - Stein, A. S.

AU - Nademanee, A.

AU - Krishnan, A.

AU - Kogut, N.

AU - Forman, S. J.

AU - Bhatia, S.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - The probability of survival is conventionally calculated from autologous hematopoietic cell transplantation (aHCT). Conditional survival takes into account the changing probability of survival with time survived, but this is not known for aHCT populations. We determined disease- and cause-specific conditional survival for 2388 patients treated with aHCT over a period of 20 years at a single institution. A total of 1054 deaths (44% of the cohort) were observed: 78% attributed to recurrent disease; 9% to subsequent malignancies and 6% to cardiopulmonary disease. Estimated probability of relative survival was 62% at 5 years and 50% at 10 years from aHCT. On the other hand, the 5-year relative survival was 70, 75, 81 and 88% after having survived 1, 2, 5 and 10 years after aHCT, respectively. The cohort was at a 13.9-fold increased risk of death compared with the general population (95% confidence interval (CI)=13.1-14.8). The risk of death approached that of the general population for 10-year survivors (standardized mortality ratio (SMR)=1.4, 95% CI=0.9-1.9), with the exception of female Hodgkin's lymphoma patients transplanted before 1995 at age ≤40 years (SMR=6.0, 95% CI=1.9-14.0). Among those who had survived 10 years, nonrelapse-related mortality rates exceeded relapse-related mortality rates. This study provides clinically relevant survival estimates after aHCT, and helps inform interventional strategies.

AB - The probability of survival is conventionally calculated from autologous hematopoietic cell transplantation (aHCT). Conditional survival takes into account the changing probability of survival with time survived, but this is not known for aHCT populations. We determined disease- and cause-specific conditional survival for 2388 patients treated with aHCT over a period of 20 years at a single institution. A total of 1054 deaths (44% of the cohort) were observed: 78% attributed to recurrent disease; 9% to subsequent malignancies and 6% to cardiopulmonary disease. Estimated probability of relative survival was 62% at 5 years and 50% at 10 years from aHCT. On the other hand, the 5-year relative survival was 70, 75, 81 and 88% after having survived 1, 2, 5 and 10 years after aHCT, respectively. The cohort was at a 13.9-fold increased risk of death compared with the general population (95% confidence interval (CI)=13.1-14.8). The risk of death approached that of the general population for 10-year survivors (standardized mortality ratio (SMR)=1.4, 95% CI=0.9-1.9), with the exception of female Hodgkin's lymphoma patients transplanted before 1995 at age ≤40 years (SMR=6.0, 95% CI=1.9-14.0). Among those who had survived 10 years, nonrelapse-related mortality rates exceeded relapse-related mortality rates. This study provides clinically relevant survival estimates after aHCT, and helps inform interventional strategies.

UR - http://www.scopus.com/inward/record.url?scp=84877617679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877617679&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.311

DO - 10.1038/leu.2012.311

M3 - Article

VL - 27

SP - 1139

EP - 1145

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -